Innate Pharma Announces €15M Investment by Sanofi – Company Announcement - FT.com
Summary
The newly issued shares will be admitted to trading on the regulated market of Euronext in on the same day.The tables below set out the Companys shareholding, based on the information available to Innate as of the date of this press release, before and after the closing of the capital increase:is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET\xae (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).Innates portfolio includes several ANKET\xae drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.Headquartered in with a US office in , is listed on Euronext Paris and Nasdaq in the US.Learn more about at www.innate-pharma.com and follow us on LinkedIn and X.This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys reliance on third parties to manufacture its product candidates, the Companys commercialization efforts and the Companys continued ability to raise capital to fund its development.